Figure 5
AZD6244 reduces tumor growth and angiogenesis without hepatic and renal toxicity in SGC7901 xenografts.
The degree of differentiation was comparable between two groups; however, increased necrosis of tumor was visualized in the AZD6244 group (A). No significant pathologic change was observed in liver (B) and kidney (C). The tumor weight was significantly decreased after treatment with AZD6244 at a dosage of 50 mg/kg/day when compared to that treatment with vehicle (D). ERK were comparable between two groups and much more positive staining of CD 31, VEGF and p-ERK (E) visualized by IHC was observed in the control group when compared with that in AZD6244 group. Consistently, the MVD (F), mRNA (G,I) and protein (H) of VEGF were remarkably reduced after treatment with AZD6244 at a dosage of 50 mg/kg/day. Both mRNA and protein of ERK were comparable between two groups (J,K); however, the p-ERK was dramatically reduced in AZD6244 group when compared with that in control group (G). # p < 0.05 vs. control group.
